Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Consumer OTC Drugs

Antineoplaston researcher Burzynski indicted by federal grand jury on 75 fraud counts.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

ANTINEOPLASTON PROMOTER BURZYNSKI INDICTED BY HOUSTON FEDERAL GRAND JURY on 75 counts of mail fraud, contempt and FDA violations, Southern Texas U.S. Attorney Gaynelle Griffin Jones announced Nov. 20. Thirty-four counts of the federal indictment charge Houston physician Stanislaw Burzynski, MD, with mail fraud, while 40 counts cite him for introducing an unapproved drug into interstate commerce.
Table

View full table

Advertisement

Topics

Advertisement
Tags:
Consumer OTC Drugs
UsernamePublicRestriction

Register

PS084520

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By